ArticleApplied health economics and health policy2020
Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT
Article in Applied health economics and health policy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- The impact of switching from single-use to reusable healthcare products: a transparency checklist and systematic review of life-cycle assessments.European journal of public health · 2023Pooled it
- Managing Inhaler Environmental Sustainability and Effective Respiratory Care: Current Evidence, Challenges, and Opportunities.Pharmaceutical medicine · 2026Article
- Points to consider for incorporating climate impacts into health economic evaluation.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Life Cycle Assessments in Healthcare: Insights and Standardisation Needs.International journal of environmental research and public health · 2026Review
- Which Factors are Holding up the Integration of the Environmental Impact of Health Technologies in Health Technology Assessment? Insights from a Multi-Stakeholder Interview Study.Applied health economics and health policy · 2026Article
- Integrating Environmental Impact in Health Technology Assessment: An Exploratory Study.PharmacoEconomics · 2025Article
- Towards the Operationalization of Health Technology Sustainability Assessment and the Early Eco Design of the Internet of Medical Things.Sensors (Basel, Switzerland) · 2025Article
- Cost of Carbon in the Total Cost of a Healthcare Procedure: Example of Micro-Costing Study in a French Setting.Applied health economics and health policy · 2025Article
- Integrating environmental sustainability into health technology assessment: an international survey of HTA stakeholders.International journal of technology assessment in health care · 2024Article
- Cost of Carbon in the Total Cost of Healthcare Procedures: A Methodological Challenge.Applied health economics and health policy · 2024Article
- Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines.Frontiers in immunology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRESPIMAT
objectiveThe objective of this study was to perform an economic evaluation that incorporates the ecological impact of adopting RESPIMAT re-usable into the healthcare system in Germany.
methodsInhaler costs and environmental impact over 5 years in Germany in a scenario with RESPIMAT re-usable compared to a scenario without RESPIMAT re-usable were estimated using a budget impact model. The carbon emissions were derived for each treatment pattern considering the whole life cycle (cradle-to-grave) of the inhaler product. The cost of carbon emissions was estimated using a societal cost per ton of carbon emission.
resultsBy introducing RESPIMAT re-usable in Germany, it was estimated that by 2023, the number of inhalers used would have decreased by 5,748,750 compared to a scenario without RESPIMAT re-usable. In addition, this measure would reduce the environmental burden of inhaler use while at the same time reducing medical cost of inhalers.
conclusionsAdopting RESPIMAT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.